Cambridge, Massachusetts-based Biogen is developing it with Japan’s Eisai Co. In afternoon trading, the companies’ stocks were up roughly 4%. The stakes are high for approval or denial.
More Experts split sharply over experimental new Alzheimer’s drug Videos